[A26-42] Finerenone (heart failure with LVEF ≥ 40%) – Benefit assessment according to §35a Social Code Book V
Last updated 03.08.2026
Project no.:
A26-42
Commission:
Commission awarded on 22.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with left ventricular ejection fraction ≥ 40%
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-42
| Project no. | Title | Status |
|---|---|---|
| A23-14 | Finerenone (CKD stage 1 and 2) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-15 | Finerenone (CKD stage 2 and 3) – Benefit assessment according to §35a Social Code Book V | Commission completed |